NCT05872854View on ClinicalTrials.gov

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2025

Conditions
Cutaneous T Cell LymphomaMycosis Fungoides
Interventions
DRUG

Hypericin

HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment

OTHER

Visible Light

After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.

Trial Locations (1)

19034

Perelman Center for Advanced Medicine, Philadelphia

Sponsors

Collaborators (1)

Soligenix
All Listed Sponsors
collaborator

Soligenix

INDUSTRY

lead

Ellen Kim, MD

OTHER